

A protocol for lentiviral infection of primary patient pancreatic tumors

Raymond Fox (✉ r1fox@ucsd.edu)

Tannishtha Reya Lab, University of California, San Diego

Tannishtha Reya (✉ treya@ucsd.edu)

Tannishtha Reya Lab, University of California, San Diego

Nikki Lytle

Tannishtha Reya Lab, University of California, San Diego

Andrew Lowy

University of California, San Diego

Method Article

Keywords: shRNA infection, PDX

Posted Date: June 20th, 2016

DOI: <https://doi.org/10.1038/protex.2016.036>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

This protocol describes a strategy for lentiviral infection of primary patient pancreatic cancer cells to assess the impact of gene modulation on tumor cell growth in xenografts.

Introduction

Pancreatic cancer is now the 3rd leading cause of cancer related deaths in the United States, and is projected to become the 2nd leading cause by 2020. A better understanding of the molecular regulation of pancreatic cancer growth may help identify new therapeutic strategies targeting this largely drug resistant disease. The development of methods to successfully deliver shRNAs to block gene expression in primary patient pancreatic tumor cells can be critical to defining the networks that control human tumor cell growth.

Reagents

• Forceps \ (FST) • Surgical Scissors \ (FST) • Betadine \ (Fisher) • Isoflurane \ (Piramal Healthcare) • RPMI 1640 \ (Gibco, Life Technologies) • Fetal Bovine Serum \ (Gemini Bio-Products) • NEAA, Pen/Strep, and Glutamax \ (all 100x from Gibco, Life Technologies) • FACS Antibody: EpCAM \ (PE) antibody was purchased from eBioscience. • RBC Lysis Buffer \ (eBioscience) • Polybrene \ (Sigma, 5ug/ml) • Human Tumor Dissociation Kit \ (Miltenyi, 130-095-929) • gentleMACS C-tubes \ (Miltenyi, 130-093-237) • Soybean Trypsin Inhibitor \ (Sigma) • BD Matrigel Growth Factor Reduced \ (BD Biosciences, 354230) • Ultra-Low attachment Flat bottom 24 well plates \ (Corning)

Equipment

• Isoflurane regulator and scavenging system \ (South Coast Anesthesia) • gentleMACS Dissociator \ (Miltenyi, 130-093-235) • MACSmix Tube rotator \ (Miltenyi, 130-090-753) • Hemocytometer • FACSAria III machine \ (Becton Dickinson)

Procedure

****Tissue Dissociation.**** \ (the procedures below are performed on mice bearing patient-derived pancreatic tumors)_ 1. Euthanize tumor-bearing mouse. 2. Spray mouse and surgical tools with 70% Ethanol. 3. Remove pancreatic tumor and immediately place into ice cold RPMI 1640 \ (no additives). Proceed with the following steps immediately following resection. 4. In RPMI 1640 \ (no additives), dissect and discard necrotic tissue. 5. In 1ml freshly prepared Miltenyi tissue dissociation media* \ (from the Human Tumor Dissociation Kit), finely mince tumor into 2-4 mm pieces. 6. Place minced tumor tissue into remaining 4 ml of dissociation medium in a gentleMACS C-tube. 7. Follow Miltenyi protocol 2.2.3 for the dissociation of tough tumors. \ (Optional) To improve the recovery of viable cells, add Soybean Trypsin Inhibitor to a final concentration of 0.2 mg/ml to Miltenyi tissue dissociation media._ ****Lentiviral**

infection Protocol.** 1. Immediately following dissociation, re-suspend cells in culture media (RPMI 1640 media supplemented with 20% FBS, 1x non-essential amino acids, 100 IU/ml penicillin, 100 µg/ml streptomycin, 1x Glutamax). 2. Count single cells using a hemocytometer. 3. Dilute cells to a concentration of 2.5×10^5 cells per 200 µl of culture media. 4. Plate 200 µl of cells per well into an Ultra-Low attachment 24 well plate. 5. Add polybrene to each well for a final concentration of 5 µg/ml. 6. Add shRNA lentivirus at an MOI >10 (~25 µl virus per condition). 7. Culture cells for 24 hours at 37°C 5% CO₂. 8. After 24 hours, collect cells, spin for 5 min at 300g, and wash twice with culture media. 9. Following the second wash, suspend cells in 50 µl of RPMI 1640 media (no additives). 10. ****Pre-transplantation analysis:**** determine the percentage of tumor cells infected by lentivirus by assessing viral tagged GFP reporter expression in epithelial cells. To this end, stain 5 µl of uninfected/infected cells with anti-mouse EpCAM-PE antibody and analyze for GFP expression by flow cytometry on a FACSAria III machine. 11. Mix the remaining 45 µl of uninfected/infected cells with 45 µl of BD Matrigel Matrix Growth Factor Reduced and place on ice until transplantation. 12. Inject cells subcutaneously into the left or right flank of 5-8 week-old NOD/SCID Il2ry^{-/-} (NSG) recipient mice. ****Post-transplantation Analysis.**** 1. Euthanize mice at 3 months post-transplant. 2. Collect, weigh, and dissociate tumors as described above. 3. Stain tumor cells with anti-mouse EpCAM-PE antibody and analyze for GFP expression by flow cytometry on a FACSAria III machine. 4. Calculate GFP contribution to the tumor mass: Tumor wet weight (g) x EpCAM⁺;GFP⁺ (%) = Weight EpCAM⁺;GFP⁺ tumor cells (g)